Showing 3781-3790 of 5646 results for "".
- RetinAI Launches Discovery Platform for Ophthalmology and Optometry Clinicshttps://modernod.com/news/retinai-discovery-platform-launched-to-improve-workflows-referrals-and-patient-management-in-ophthalmology-and-optometry-clinics/2482122/Ikerian, the parent company of RetinAI, announced the launch of 'RetinAI Discovery for Clinics,' which features AI models designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions, and patient manage
- Ocular Therapeutix Announces First Subjects Screened in Phase 3 Clinical Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-subjects-screened-in-phase-3-pivotal-clinical-trial-of-axpaxli-in-wet-amd/2482113/Ocular Therapeutix announced that the first three subjects have been screened and received their first aflibercept injection in the phase 3 SOL-1 clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degenerati
- EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restorethttps://modernod.com/news/eyebio-announces-positive-visual-anatomic-and-safety-data-from-first-in-human-ph1b2a-amarone-trial-of-restoret/2482112/Eyebiotech announced the presentation of Week 12 data from its first-in-human phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve wet age-related macular degeneration (AMD). The analysis was presented by Charles C.
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T
- Adverum Announces Positive Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd/2482107/Adverum Biotechnologies announced preliminary safety and efficacy data from the ongoing LUNA phase 2 trial in patients with wet age-related macular degeneration (AMD). These data are being presented by Arshad Khanani, MD, today at the 47th Annual Meeting of the Macula Society. The presentation, t
- Shamir Launches Spark 4W Digital Electro-Optic Measurement Systemhttps://modernod.com/news/shamir-launches-spark-4w-digital-electro-optic-measurement-system/2482101/Shamir announced the launch of the Spark 4W, a digital electro-optic measurement system based on 3D stereo vision technology and artificial intelligence (AI) elements. Shamir Spark 4W is designed to enable eye care professionals (ECPs) to obtain precise and automatic meas
- 4D Molecular Therapeutics' Gene Therapy Maintains Stable Visual Acuity in Wet AMD Patients in Phase 2 Studyhttps://modernod.com/news/new-data-shows-4d-molecular-therapeutics-gene-therapy-cuts-eylea-use-in-wet-amd-patients/2482097/4D Molecular Therapeutics announced positive interim data from the phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (AMD) patients with severe disease activity and a high treatment burden. Data presented at the Angiogenesis, Exudat
- Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eyehttps://modernod.com/news/toku-obtains-ce-and-ukca-marks-for-ai-cardiovascular-risk-assessments-through-the-eye/2482096/Toku announced that it has obtained CE Mark in Europe and UKCA in the United Kingdom for its patented CLAiR technology, which provides a non-invasive evaluation for the risk of cardiovascular disease (CVD) at the point of care using retinal images captured during a routine eye exam
- Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officerhttps://modernod.com/news/ace-vision-group-names-val-kolesnitchenko-md-as-chief-scientific-officer/2482095/Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer. Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global
- Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopiahttps://modernod.com/news/alcon-canada-launches-total30-multifocal-contact-lenses-for-reusable-lens-patients-with-presbyopia/2482093/Alcon announced the launch of TOTAL30 Multifocal in Canada, the first and only monthly water gradient multifocal contact lens. The new TOTAL30 Multifocal lens is designed to help digital device dryness by utilizing a proprietary water gradient technology to deliver nearly